Eli Lilly’s Ebglyss Shows Promise for Eczema Patients Previously Treated with Dupixent

Eli Lilly’s Ebglyss Shows Promise for Eczema Patients Previously Treated with Dupixent

Eli Lilly and Company (LLY) has announced promising results from its Phase 3b ADapt study of Ebglyss (lebrikizumab), a new treatment for moderate-to-severe atopic dermatitis (eczema). The study, which will be presented at the Fall Clinical Dermatology Conference, reveals that Ebglyss effectively improved skin and itch symptoms in patients who had previously been treated with Sanofi SA (SNY) and Regeneron Pharmaceuticals Inc’s (REGN) Dupixent (dupilumab).

The study’s primary endpoint was a 75% improvement in the Eczema Area and Severity Index (EASI-75) score at 16 weeks. This index measures the extent and severity of eczema. Notably, 57% of patients treated with Ebglyss achieved EASI-75 at Week 16 and 60% at Week 24, demonstrating sustained efficacy over time. The study also assessed the effectiveness of Ebglyss in patients who had not achieved adequate response to Dupixent, with a significant 46% achieving EASI-75 at Week 16.

Ebglyss also demonstrated impressive results in relieving itch. Patients who discontinued Dupixent and began treatment with Ebglyss experienced at least a four-point improvement in the Pruritus NRS score (a measure of itch intensity) from baseline at both Week 16 (53%) and Week 24 (62%). This indicates Ebglyss’s potential to alleviate a major symptom of eczema and improve quality of life for patients.

The study also highlighted Ebglyss’s effectiveness in treating difficult-to-treat areas of eczema. At Week 24, 52% of patients treated with Ebglyss experienced clear or almost clear face dermatitis. Additionally, patients with moderate-to-severe hand dermatitis saw a 75% decrease in the modified total lesion-symptom score at Week 24, indicating significant improvement in hand eczema.

Importantly, the safety profile of Ebglyss was favorable. Less than 6% of patients treated with Ebglyss experienced an adverse event that led to discontinuation of treatment.

The FDA granted approval for Ebglyss last month for adults and children 12 years and older weighing at least 88 pounds. This approval follows previous approvals in the European Union in 2023 and Japan in January 2024, with additional markets expected to follow later this year. Ebglyss’s targeted approach and positive clinical trial results solidify its potential as a valuable treatment option for patients with moderate-to-severe atopic dermatitis, particularly those who have not achieved satisfactory control with existing therapies. The drug’s approval and ongoing expansion into new markets suggest a promising future for Ebglyss in the treatment of eczema.